{"id":787494,"date":"2023-10-02T16:40:18","date_gmt":"2023-10-02T20:40:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/"},"modified":"2023-10-02T16:40:18","modified_gmt":"2023-10-02T20:40:18","slug":"shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/","title":{"rendered":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Oct.  02, 2023  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc.:<\/p>\n<p>On September 19, 2023, ARS announced it received from the Food and Drug Administration (FDA) a Complete Response Letter (CRL) concerning ARS\u2019 \u201cneffy.\u201d \u201cNeffy\u201d is a nasally administered epinephrine dose used in cases of severe allergic reactions. The CRL indicated ARS must complete additional studies on \u201cneffy\u201d before the FDA can consider further the drug\u2019s approval. In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions. Following this news, ARS\u2019 stock price fell by $4.52 per share, or approximately 61% to close at $2.92 per share.<\/p>\n<p>Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain ARS investors. If you incurred a loss on your SPRY investment, please contact us using the link below to discuss your rights.<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tfHnxmPCX9VgTLIaMmAhZsXqrny-MJp-Bnr3luXk7osmeXE9LdWtelPxxfc_avhiJM_aXRzxCC3YTrOIBjHpliyIbThY-s9wDcVpknUBedHRe2DVna0xx8QmsEEggl2TUjo0hBVp4Zntzz5X2F8ervBOQAjUQIZGH_d-qumACJ47a5K-M0PiROd16j2zIFqvLfSdejYKzRM34cdk9zaQAZH3JAnYL7KEOnJa3zdZ8frwvGQKjVm05iGWgSjwaTAxBwZjmBs-QNsP5DI8cN426Q==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/ars-loss-submission-form\/?id=50104&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c2DWN1ch9CzuN5FkLrClIj5zI9hP4RU44iwC3_1U98YjkaG_OHhB888Y-DbUEcoay1i0kY7ANW7-5EVFP6P2o-HvalCS4wRWxgJ7AjTDgIWtTVuDDBLkgwLzFLI4Tz3M\" rel=\"nofollow noopener\" target=\"_blank\">dg@securitiesclasslaw.com<\/a><br \/>Phone: (646) 453-8903<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Njk2MTQ0NzQtY2ZjMS00YzhiLWFiY2QtNDkyMDk5YWI0MDA2LTEyNzA0Njc=\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc.: On September 19, 2023, ARS announced it received from the Food and Drug Administration (FDA) a Complete Response Letter (CRL) concerning ARS\u2019 \u201cneffy.\u201d \u201cNeffy\u201d is a nasally administered epinephrine dose used in cases of severe allergic reactions. The CRL indicated ARS must complete additional studies on \u201cneffy\u201d before the FDA can consider further the drug\u2019s approval. In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions. Following this news, ARS\u2019 stock price fell by $4.52 per share, or approximately 61% to close at $2.92 per share. Due to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-787494","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc.: On September 19, 2023, ARS announced it received from the Food and Drug Administration (FDA) a Complete Response Letter (CRL) concerning ARS\u2019 \u201cneffy.\u201d \u201cNeffy\u201d is a nasally administered epinephrine dose used in cases of severe allergic reactions. The CRL indicated ARS must complete additional studies on \u201cneffy\u201d before the FDA can consider further the drug\u2019s approval. In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions. Following this news, ARS\u2019 stock price fell by $4.52 per share, or approximately 61% to close at $2.92 per share. Due to &hellip; Continue reading &quot;SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-02T20:40:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)\",\"datePublished\":\"2023-10-02T20:40:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/\"},\"wordCount\":304,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/\",\"name\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=\",\"datePublished\":\"2023-10-02T20:40:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY) - Market Newsdesk","og_description":"NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc.: On September 19, 2023, ARS announced it received from the Food and Drug Administration (FDA) a Complete Response Letter (CRL) concerning ARS\u2019 \u201cneffy.\u201d \u201cNeffy\u201d is a nasally administered epinephrine dose used in cases of severe allergic reactions. The CRL indicated ARS must complete additional studies on \u201cneffy\u201d before the FDA can consider further the drug\u2019s approval. In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions. Following this news, ARS\u2019 stock price fell by $4.52 per share, or approximately 61% to close at $2.92 per share. Due to &hellip; Continue reading \"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-02T20:40:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)","datePublished":"2023-10-02T20:40:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/"},"wordCount":304,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/","name":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=","datePublished":"2023-10-02T20:40:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkzMTMzOSM1ODQwNDM2IzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-ars-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit-nasdaq-spry\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit \u2013 (NASDAQ: SPRY)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=787494"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787494\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=787494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=787494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=787494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}